Last 12 months
Inside the activity.
0 purchase rows · 53 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 17 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 17 |
| Sep 2026 | 0 | 11 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2020 Filed Aug 20, 2020 20:06 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 21,614 | $127.63 | $2,758,594.82 |
DisclosureSEC source: 0001567619-20-015809 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,880,306 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $125.965 to $128.89. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 20:12 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 16,589 | $127.26 | $2,111,116.14 |
DisclosureSEC source: 0001567619-20-015812 · doc1.xml · nonDerivative · entry 1 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,901,920 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $126.55 to $128.57. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 20:06 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 16,589 | $127.26 | $2,111,116.14 |
DisclosureSEC source: 0001567619-20-015809 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,901,920 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $126.55 to $128.57. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 20:47 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 16,485 | $128.18 | $2,113,047.30 |
DisclosureSEC source: 0001567619-20-015706 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,918,509 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $126.925 to $128.97. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 20:46 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 16,485 | $128.18 | $2,113,047.30 |
DisclosureSEC source: 0001567619-20-015705 · doc1.xml · nonDerivative · entry 2 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,918,509 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $126.925 to $128.97. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:06 UTC |
GEIGER JESSE JCFO & COO, Lab Operations
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $23.00 | $0.00 |
DisclosureSEC source: 0001567619-20-015751 · doc1.xml · derivative · entry 3 GEIGER JESSE J · CIK 0001677399 · CFO & COO, Lab Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,010 Underlying: Common Stock · 3,500 shares Expires 2023-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each option vested on August 10, 2020. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:06 UTC |
GEIGER JESSE JCFO & COO, Lab Operations
|
SaleCommon Stock | 3,500 | $128.00 | $448,000.00 |
DisclosureSEC source: 0001567619-20-015751 · doc1.xml · nonDerivative · entry 2 GEIGER JESSE J · CIK 0001677399 · CFO & COO, Lab Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,382 Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:06 UTC |
GEIGER JESSE JCFO & COO, Lab Operations
|
Exercise / conversionCommon Stock | 3,500 | $23.00 | $80,500.00 |
DisclosureSEC source: 0001567619-20-015751 · doc1.xml · nonDerivative · entry 1 GEIGER JESSE J · CIK 0001677399 · CFO & COO, Lab Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 20:47 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 16,857 | $127.07 | $2,142,018.99 |
DisclosureSEC source: 0001567619-20-015706 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,934,994 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $126.17 to $128.64. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 20:46 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 16,857 | $127.07 | $2,142,018.99 |
DisclosureSEC source: 0001567619-20-015705 · doc1.xml · nonDerivative · entry 1 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,934,994 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $126.17 to $128.64. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:58 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 16,671 | $127.87 | $2,131,720.77 |
DisclosureSEC source: 0001567619-20-015531 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,951,851 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $126.565 to $129.03. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:55 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 16,671 | $127.87 | $2,131,720.77 |
DisclosureSEC source: 0001567619-20-015527 · doc1.xml · nonDerivative · entry 2 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,951,851 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $126.565 to $129.03. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:58 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 21,916 | $127.21 | $2,787,934.36 |
DisclosureSEC source: 0001567619-20-015531 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,968,522 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $124.06 to $128.05. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:55 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 21,916 | $127.21 | $2,787,934.36 |
DisclosureSEC source: 0001567619-20-015527 · doc1.xml · nonDerivative · entry 1 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,968,522 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $124.06 to $128.05. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 20:23 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 38,642 | $125.30 | $4,841,842.60 |
DisclosureSEC source: 0001567619-20-014917 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,990,438 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $122.30 to $127.205. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 20:22 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 38,642 | $125.30 | $4,841,842.60 |
DisclosureSEC source: 0001567619-20-014915 · doc1.xml · nonDerivative · entry 2 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,990,438 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $122.30 to $127.205. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:23 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 48,148 | $120.79 | $5,815,796.92 |
DisclosureSEC source: 0001567619-20-014917 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 7,029,080 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $117.345 to $122.90. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:22 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 48,148 | $120.79 | $5,815,796.92 |
DisclosureSEC source: 0001567619-20-014915 · doc1.xml · nonDerivative · entry 1 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,029,080 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $117.345 to $122.90. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:22 UTC |
EWALD STEPHEN PGeneral Counsel & Corp. Secy.
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,400 | $0.00 Strike: $23.00 | $0.00 |
DisclosureSEC source: 0001567619-20-014914 · doc1.xml · derivative · entry 3 EWALD STEPHEN P · CIK 0001677297 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,400 shares Expires 2023-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each option vested on August 10, 2020. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:22 UTC |
EWALD STEPHEN PGeneral Counsel & Corp. Secy.
|
SaleCommon Stock | 7,400 | $121.57 | $899,618.00 |
DisclosureSEC source: 0001567619-20-014914 · doc1.xml · nonDerivative · entry 2 EWALD STEPHEN P · CIK 0001677297 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,336 F1 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $120.00 to $122.885. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:22 UTC |
EWALD STEPHEN PGeneral Counsel & Corp. Secy.
|
Exercise / conversionCommon Stock | 7,400 | $23.00 | $170,200.00 |
DisclosureSEC source: 0001567619-20-014914 · doc1.xml · nonDerivative · entry 1 EWALD STEPHEN P · CIK 0001677297 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 20:10 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 19,942 | $123.63 | $2,465,429.46 |
DisclosureSEC source: 0001567619-20-014632 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 7,077,228 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $121.485 to $124.925. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 20:09 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 19,942 | $123.63 | $2,465,429.46 |
DisclosureSEC source: 0001567619-20-014631 · doc1.xml · nonDerivative · entry 2 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,077,228 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $121.485 to $124.925. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:11 UTC |
BURWIG SUSAN EExec. VP, Operations
|
SaleCommon Stock | 7,000 | $126.00 | $882,000.00 |
DisclosureSEC source: 0001567619-20-014633 · doc1.xml · nonDerivative · entry 1 BURWIG SUSAN E · CIK 0001677418 · Exec. VP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,179 Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:10 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 15,033 | $122.43 | $1,840,490.19 |
DisclosureSEC source: 0001567619-20-014632 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 7,097,170 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $121.47 to $126.09. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:09 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 15,033 | $122.43 | $1,840,490.19 |
DisclosureSEC source: 0001567619-20-014631 · doc1.xml · nonDerivative · entry 1 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,097,170 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $121.47 to $126.09. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 05, 2020 Filed Aug 6, 2020 20:55 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 13,179 | $125.04 | $1,647,902.16 |
DisclosureSEC source: 0001567619-20-014435 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 7,112,203 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $123.48 to $125.905. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 05, 2020 Filed Aug 6, 2020 20:54 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 13,179 | $125.04 | $1,647,902.16 |
DisclosureSEC source: 0001567619-20-014433 · doc1.xml · nonDerivative · entry 2 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,112,203 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $123.48 to $125.905. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 04, 2020 Filed Aug 6, 2020 20:55 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 45,488 | $124.43 | $5,660,071.84 |
DisclosureSEC source: 0001567619-20-014435 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 7,125,382 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $123.12 to $126.605. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 04, 2020 Filed Aug 6, 2020 20:54 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 45,488 | $124.43 | $5,660,071.84 |
DisclosureSEC source: 0001567619-20-014433 · doc1.xml · nonDerivative · entry 1 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,125,382 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $123.12 to $126.605. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 20:13 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 27,005 | $124.13 | $3,352,130.65 |
DisclosureSEC source: 0001567619-20-014145 · doc1.xml · nonDerivative · entry 2 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,170,870 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $120.485 to $125.76. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 20:12 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 27,005 | $124.13 | $3,352,130.65 |
DisclosureSEC source: 0001567619-20-014144 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 7,170,870 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $120.485 to $125.76. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 20:13 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 39,622 | $118.17 | $4,682,131.74 |
DisclosureSEC source: 0001567619-20-014145 · doc1.xml · nonDerivative · entry 1 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,197,875 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $116.665 to $119.97. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 20:12 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 39,622 | $118.17 | $4,682,131.74 |
DisclosureSEC source: 0001567619-20-014144 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 7,197,875 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $116.665 to $119.97. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 30, 2020 Filed Jul 31, 2020 20:12 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 42,955 | $120.79 | $5,188,534.45 |
DisclosureSEC source: 0001567619-20-013982 · doc1.xml · nonDerivative · entry 2 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,237,497 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $118.495 to $124.015. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| July 30, 2020 Filed Jul 31, 2020 20:11 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 42,955 | $120.79 | $5,188,534.45 |
DisclosureSEC source: 0001567619-20-013981 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 7,237,497 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $118.495 to $124.015. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 30, 2020 Filed Aug 4, 2020 19:17 UTC |
BURWIG SUSAN EExec. VP, Operations
|
SaleCommon Stock | 6,000 | $121.14 | $726,840.00 |
DisclosureSEC source: 0001567619-20-014140 · doc1.xml · nonDerivative · entry 1 BURWIG SUSAN E · CIK 0001677418 · Exec. VP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,179 Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 20:12 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 47,106 | $123.99 | $5,840,672.94 |
DisclosureSEC source: 0001567619-20-013982 · doc1.xml · nonDerivative · entry 1 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,280,452 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $120.925 to $125.405. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 20:11 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 47,106 | $123.99 | $5,840,672.94 |
DisclosureSEC source: 0001567619-20-013981 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 7,280,452 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $120.925 to $125.405. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 20:14 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 214,499 | $127.23 | $27,290,707.77 |
DisclosureSEC source: 0001567619-20-013885 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 7,327,558 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $116.765 to $143.965. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 20:12 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 214,499 | $127.23 | $27,290,707.77 |
DisclosureSEC source: 0001567619-20-013884 · doc1.xml · nonDerivative · entry 2 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,327,558 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $116.765 to $143.965. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 20:14 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 29,019 | $110.43 | $3,204,568.17 |
DisclosureSEC source: 0001567619-20-013885 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 7,542,057 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $106.69 to $112.55. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 20:12 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 29,019 | $110.43 | $3,204,568.17 |
DisclosureSEC source: 0001567619-20-013884 · doc1.xml · nonDerivative · entry 1 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,542,057 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $106.69 to $112.55. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| July 24, 2020 Filed Jul 27, 2020 20:12 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 34,380 | $106.13 | $3,648,749.40 |
DisclosureSEC source: 0001567619-20-013761 · doc1.xml · nonDerivative · entry 2 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,571,076 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $105.41 to $110.04. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| July 24, 2020 Filed Jul 27, 2020 20:11 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 34,380 | $106.13 | $3,648,749.40 |
DisclosureSEC source: 0001567619-20-013760 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 7,571,076 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $105.41 to $110.04. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 20:12 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 31,743 | $111.83 | $3,549,819.69 |
DisclosureSEC source: 0001567619-20-013761 · doc1.xml · nonDerivative · entry 1 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,605,456 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $109.82 to $114.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 20:11 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 31,743 | $111.83 | $3,549,819.69 |
DisclosureSEC source: 0001567619-20-013760 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 7,605,456 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $109.82 to $114.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 20:23 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 35,878 | $109.99 | $3,946,221.22 |
DisclosureSEC source: 0001567619-20-013639 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 7,637,199 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $106.89 to $111.26. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 20:20 UTC |
Medpace Investors, LLC10% owner
|
SaleCommon Stock | 35,878 | $109.99 | $3,946,221.22 |
DisclosureSEC source: 0001567619-20-013636 · doc1.xml · nonDerivative · entry 2 Medpace Investors, LLC · CIK 0001524599 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,637,199 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $106.89 to $111.26. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 20:23 UTC |
Troendle August J.Director · President & CEO · 10% owner
|
SaleCommon Stock | 28,090 | $106.78 | $2,999,450.20 |
DisclosureSEC source: 0001567619-20-013639 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 7,673,077 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $105.32 to $107.74. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.